Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for AtriCure (ATRC) over the last 17 years, with Q3 2025 value amounting to $7.4 million.

  • AtriCure's Other Non-Current Liabilities rose 51205.32% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 51205.32%. This contributed to the annual value of $1.2 million for FY2024, which is 194.49% down from last year.
  • AtriCure's Other Non-Current Liabilities amounted to $7.4 million in Q3 2025, which was up 51205.32% from $1.2 million recorded in Q2 2025.
  • AtriCure's 5-year Other Non-Current Liabilities high stood at $192.5 million for Q2 2021, and its period low was $1.2 million during Q2 2025.
  • In the last 5 years, AtriCure's Other Non-Current Liabilities had a median value of $1.2 million in 2022 and averaged $21.6 million.
  • As far as peak fluctuations go, AtriCure's Other Non-Current Liabilities plummeted by 9936.89% in 2022, and later surged by 51205.32% in 2025.
  • Over the past 5 years, AtriCure's Other Non-Current Liabilities (Quarter) stood at $1.2 million in 2021, then increased by 0.49% to $1.2 million in 2022, then grew by 0.65% to $1.2 million in 2023, then decreased by 1.94% to $1.2 million in 2024, then soared by 508.51% to $7.4 million in 2025.
  • Its last three reported values are $7.4 million in Q3 2025, $1.2 million for Q2 2025, and $1.2 million during Q1 2025.